18836658Sattler M, Abidoye O, Salgia RTheScientificWorldJournalAntibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Head and Neck Neoplasms; Lung NeoplasmsAntibodies, Monoclonal, Humanized; Bevacizumab; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Panitumumab; Protein Kinase Inhibitors; QuinazolinesEGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.ScientificWorldJournal2008-09-21T00:00:002008EGFR-targeted therapeutics: focus on SCCHN and NSCLC.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD002294Disorders19910750.588875Carcinoma, Squamous CellD000911Chemicals & Drugs33713760.622785Antibodies, MonoclonalD002289Disorders15810730.519185Carcinoma, Non-Small-Cell LungD003131Procedures38816800.739615Combined Modality TherapyD008175Disorders32822600.404557Lung NeoplasmsAuthorship 362333D006258Disorders15210510.576809Head and Neck NeoplasmsD006801Living Beings2262862810.130064HumansD019008Physiology1805890.751147Drug Resistance, Neoplasm0.3410810.3410811authors10.2517has subject areaD011799Chemicals & Drugs652200.877248QuinazolinesD061067Chemicals & Drugs2139290.656201Antibodies, Monoclonal, HumanizedD002986Procedures32811680.665262Clinical Trials as TopicD000068258732810.891448BevacizumabD000068818471130.945058CetuximabD00006934738900.973312Erlotinib HydrochlorideD066246Chemicals & Drugs1494850.779557ErbB ReceptorsD047428Chemicals & Drugs2065890.714226Protein Kinase InhibitorsMedicineUniversity of ChicagoRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professor